Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma
Advanced Science · 2026
DOI: 10.1002/advs.77811 ↗At a glance
Übersichtsarbeit in Advanced Science, 2026. Written by Alexandra R Paul and 4 co-authors. Institution: Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Major MEDLINE topics: Glioblastoma, Aptamers, Nucleotide, Drug Delivery Systems, Brain Neoplasms. Cited 1 times so far (Crossref); 142 references. The full text is freely available (open access, CC BY 4.0). Funded by: King's College London, University of London Maplethorpe Fellowship and Brain Research UK.
Abstract (original language)
Therapeutic strategies for glioblastoma have progressed considerably over recent decades. Despite the development of new biomedical technologies and advances in our understanding of physiology and disease progression, effective drug delivery to brain cancer remains a significant challenge. The challenge is delivering therapeutics to the correct location without losing therapeutics to non‐desirable cells as well as overcoming the low permeability posed by the blood‐brain barrier. This could be tackled by conjugating a specific targeting agent to the therapeutic or drug delivery system to guide, such as an aptamer. Aptamers are short, single‐stranded oligonucleotides with high selectivity and specificity for their targets, making them primed for a vast array of diagnostic and therapeutic applications. Aptamers are powerful molecular tools with the potential to overcome many of the challenges inherent in treating brain‐based diseases. Here is discussed the use of aptamers, specifically as drug delivery vehicles, for the treatment of glioblastoma. There are a multitude of drug delivery aptamers in development, each with their own optimized formulation and drug delivery strategy. This review systematically and comprehensively details every drug delivery system that includes aptamers as a glioblastoma therapy that has been published to date.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.
ORCID profiles: Alexandra R Paul, Yutong Luo, Khuloud T Al-Jamal
Funding
- King's College London, University of London Maplethorpe Fellowship and Brain Research UK
Cite
APA
Paul, A. R., Mitchell, A. M., O'Neil, D., Luo, Y., & Al-Jamal, K. T. (2026). Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma. Advanced Science. https://doi.org/10.1002/advs.77811
Vancouver
Paul AR, Mitchell AM, O'Neil D, Luo Y, Al-Jamal KT. Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma. Advanced Science. 2026. doi:10.1002/advs.77811
BibTeX
@article{Paul2026,
author = {Paul, Alexandra R and Mitchell, Alexandra Moreno and O'Neil, Dean and Luo, Yutong and Al-Jamal, Khuloud T},
title = {Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.77811}
}
EUVIMED